Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D6-25-hydroxyvitamin D3 (hexadeuterated 25(OH)D3) is a stable isotope-labeled tracer used in pharmacokinetic research to study the metabolism and clearance of vitamin D. Developed and utilized by researchers at the University of Washington, specifically in the CLEAR (Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease) study, this compound allows for the precise measurement of 25-hydroxyvitamin D3 (calcifediol) clearance rates without the risks associated with radioactive tracers. It is primarily used as a research tool to investigate how chronic kidney disease (CKD) and factors like race or vitamin D supplementation affect the metabolic breakdown and elimination of vitamin D3 metabolites. By administering the compound intravenously, researchers can track its clearance through the vitamin D metabolic pathway, providing insights into the pathophysiology of vitamin D deficiency in CKD patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d6-25-hydroxyvitamin D3.